CORBUS PHARMACEUTICALS HOLDINGS

Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin 4-on cancer cells to release a cytotoxic payload and CRB-601, and anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells... Corbus is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline encompasses two different approaches to oncology with different risk profiles: a next-generation Nectin -4 Antibody Drug Conjugate (ADC) and monoclonal antibodies that target integrins to inhibit activation of TGFβ. Corbus is headquartered in Norwood, Massachusetts.

Also known as: Corbus, Corbus Pharmaceuticals Holdings, Inc.

Primary location: Norwood United States